What Are The Research Benefits of HGH Fragment 176-191
Weight Loss and Fat Burning
Fragment 176-191, known as the “lipolytic fragment,” has shown significant fat-burning and weight-loss effects in studies on mice (1). These effects are linked to increased beta-3 adrenergic receptor (ADRB3) activity (2), which promotes fat burning in adipose tissue and thermogenesis in skeletal muscle (3). A study by Frank NG M.D. from Monash University, Australia discovered obese mice experienced nearly 50% less weight gain after using the fragment. In comparison lean mice maintained their normal weight, suggesting regulatory pathways prevent further weight loss when body weight is ideal (4). These findings highlight potential avenues for further research into energy regulation and weight management.
Safety Studies
Human growth hormone derivatives have raised concerns over risks such as insulin resistance, diabetes, acromegaly, cancer, hypertension, and edema (5). However, a 2013 meta-analysis found no significant negative effects linked to to the peptide when tested in randomized, double-blind, placebo-controlled studies, whether given intravenously or orally (6).
The study showed no changes in physical exams, lab results, glucose levels, glucose tolerance, insulin sensitivity, IGF-1 levels, or adverse event rates.
It may offer the benefits of hGH without the associated risks, making it a potentially safer option for therapeutic use.
Blood Sugar Regulation
{name] Research on animals has shown that the C-terminal end of human growth hormone plays a key role in its ability to lower blood sugar levels (7). Research on multiple fragments of this specific hGH section has identified fragment 176-191 as the most effective synthetic derivative for lowering blood sugar levels. This hypoglycemic effect is linked to a prolonged elevation in plasma insulin levels. There is growing interest in exploring it as a potential treatment for prediabetes and type 2 diabetes (8).
Supports Cartilage Repair
It may enhance the effects of hyaluronic acid (HA) injections in encouraging cartilage regeneration. Europe Studies conducted on rabbits have shown that weekly injections of the peptide significantly increase markers of cartilage growth (9).
Furthermore, co-administration of Fragment 176-191 with HA has been observed to produce more substantial outcomes compared to using either treatment independently. This peptide, whether used alone or in conjunction with HA, shows potential in reducing disability associated with osteoarthritis. Such findings could pave the way for advanced therapies for osteoarthritis and possibly minimise the need for surgical intervention.
Enhancing Breast Cancer Chemotherapy
Recent Europe research has explored improving breast cancer chemotherapy using Chitosan nanoparticles loaded with both doxorubicin and an human GH fragment (176–191 peptide). Studies showed that the peptide fragment increases doxorubicin’s binding to breast cancer proteins, boosting its anticancer effects in MCF-7 cells. Nanoparticles carrying both doxorubicin and the human GH fragment were more effective and performed better than those carrying only doxorubicin. This approach offers a promising way to make chemotherapy more effective while reducing side effects (10).
Buy HGH Fragment 176-191 Peptidel Vial Europe for research online today! Available as lyophilised powder in 2 mg, 5 mg, and 10 mg vials. Available as a kit which includes syringes and bacteriostatic water for reconstituting the lyophilised powder.
References For Further Reading
(1) M Heffernan, R J Summers, A Thorburn, E Ogru, et al (2001) The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice – Endocrinology, 2001 Dec, Volume 142 (Issue 12), Pages 5182-9.
(2) Raquel Ferrer-Lorente, Cristina Cabot, José-Antonio Fernández-López, and Marià Alemany (2005) Combined effects of oleoyl-estrone and a beta3-adrenergic agonist (CL316,243) on lipid stores of diet-induced overweight male Wistar rats – Life Sciences, 2005 Sep 2, Volume 77 (Issue 16), Pages 2051-8.
(3) M A Heffernan, W J Jiang, A W Thorburn, and F M Ng (2000) Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism – American Journal of Physiology, Endocrinology & Metabolism, 2000 Sep, Volume 279 (Issue 3), Pages E501-7.
(4) F M Ng, J Sun, L Sharma, R Libinaka, W J Jiang, and R Gianello (2000) Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone – Hormone Research, 2000, Volume 53 (Issue 6), Pages 274-8.
(5) M A Heffernan, A W Thorburn, B Fam, R Summers, et al (2001) Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment – International Journal of Obesity and Related Metabolic Disorders, 2001 Oct, Volume 25 (Issue 10), Pages 1442-9.
(6) Heike Stier, Evert Vos, and David Kenley (2013) Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans – Journal of Endocrinology & Metabolism, 2013, Volume 3 (Issue 1-2), Pages 7-15.
(7) F M Ng and J Bornstein (1978) Hyperglycemic action of synthetic C-terminal fragments of human growth hormone – American Journal if Physiology, 1978 May, Volume 234 (Issue 5), Pages E521-6.
(8) Jesús Devesa, Cristina Almengló, and Pablo Devesa (2016) Multiple Effects of Growth Hormone in the Body: Is it Really the Hormone for Growth? – Clinical Medicine Insights: Endocrinology and Diabetes, 2016 Oct 12, Volume 9, Pages 47–71.
(9) Dong Rak Kwon and Gi Young Park (2015) Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model – Annals of Clinical and Laboratory Science, 2015 Summer, Volume 45 (Issue 4), Pages 426-32.
(10) Mahmoud M Habibullah, Syam Mohan, Nabeel Kashan Syed, Hafiz A Makeen, et al (2022) Human Growth Hormone Fragment 176–191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells – Drug Design, Development & Therapy, 2022 Jun 27, Volume 16, Pages 1963–1974.